Menlo Park, California-based Gauss, has announced the expansion of its Series C funding round as it has raised an additional $10 million now. It had previously raised $20 million in Series C financing. The fresh additional funding was led by 4100 Group with participation by existing investors including Softbank Ventures Asia, Northwell Health, Providence Health and Services, OSF Healthcare and Polaris Partners.
The company has raised the additional funding to accelerate its COVID-19 at-home rapid antigen test and computer-vision app. This has brought the total funding raised in Series C round to $30 million. As part of the additional funding round, 4100 Group’s MD of Private Market Investments, Scott Lancaster is joining Gauss’s Board of Directors.
“AI-driven, digital innovation platforms are critical in the battle against COVID-19, driving new models of distributed care,” said Dr. Scott Lancaster. “We’re very excited to be investing in Gauss as we see the company leading this transformation.”
Gauss is the leading developer of computer vision applications for healthcare. The additional financing will fund the clinical trials and broader post-market studies on the at-home testing platform. Its at-home testing platform is helping a major study from the Stanford University School of Medicine called Community Alliance to Test Coronavirus at Home (CATCH).